The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC).

Loren S.  Michel

Research Funding - Celgene (Inst)

Travel, Accommodations, Expenses - VentiRx

Jessica C.  Ley

Travel, Accommodations, Expenses - VentiRx

Tanya Marya  Wildes

No Relationships to Disclose

Kathryn  Trinkaus

No Relationships to Disclose

Douglas  Adkins

Research Funding - AstraZeneca (Inst); Celgene (Inst); Galera Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Soligenix (Inst); VentiRx (Inst)